Drug intelligence / Profile preview

adebrelimab + nab-paclitaxel + epirubicin + cyclophosphamide

Development stage: Phase 2
Lead developer: Hengrui Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of adebrelimab (an immune checkpoint inhibitor), nab-paclitaxel (a novel solvent-free formulation of paclitaxel), epirubicin (an anthracycline), and cyclophosphamide (an alkylating agent). The combination is being studied for use in neoadjuvant chemotherapy for breast cancer. Nab-paclitaxel followed by epirubicin/cyclophosphamide has demonstrated promising anti-tumor activity and acceptable tolerability in clinical trials for triple-negative breast cancer and other breast cancer subtypes.

Other names: Adebrelimab + nab-paclitaxel + epirubicin + cyclophosphamideSHR-1316 + nab-paclitaxel + epirubicin + cyclophosphamide

Targets

DNATOP2A (DNA topoisomerase II)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on adebrelimab + nab-paclitaxel + epirubicin + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + nab-paclitaxel + epirubicin + cyclophosphamide.